Palbociclib in liposarcoma: real-world multicenter data from the Turkish Oncology Group (TOG)

Kus F., Yildirim H. C., Bayram D., Bal O., Sahin G., Ugrakli M., ...Daha Fazla

Journal of Chemotherapy, 2025 (SCI-Expanded, Scopus) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Basım Tarihi: 2025
  • Doi Numarası: 10.1080/1120009x.2025.2557678
  • Dergi Adı: Journal of Chemotherapy
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, BIOSIS, CAB Abstracts, MEDLINE, Veterinary Science Database
  • Anahtar Kelimeler: efficacy, liposarcoma, multicenter, Palbociclib
  • Çukurova Üniversitesi Adresli: Evet

Özet

Background: Well-differentiated (WDLPS) and dedifferentiated liposarcomas (DDLPS) are subtypes with distinct behaviors, often driven by CDK4 amplification. While CDK4/6 inhibitors such as palbociclib show promise in trials, real-world data are scarce. Methods: We retrospectively analyzed 21 patients with advanced WDLPS or DDLPS treated with palbociclib monotherapy at 16 Turkish Oncology Group centers (2019–2022). Outcomes included progression-free survival (PFS), overall survival (OS), response, and safety. Results: Median age was 51 years; 38.1% had WDLPS and 61.9% DDLPS. Median PFS was 5.3 months and OS 9.1 months. The objective response rate was 0%, but disease control was achieved in 57.1%. WDLPS and earlier-line use were associated with numerically longer OS. Adverse events occurred in 71.4%, most often anemia (52.4%) and neutropenia (33.3%). Conclusion: Palbociclib showed modest activity with disease stabilization in some patients, highlighting the need for biomarker-driven and combination strategies.